What is the role of infliximab in the treatment of peripheral ulcerative keratitis (PUK)?

Updated: Jun 11, 2019
  • Author: Ellen N Yu-Keh, MD; Chief Editor: Andrew A Dahl, MD, FACS  more...
  • Print

The use of the tumor necrosis factor alpha (TNF-alpha) antagonist infliximab has been reported to be effective in rheumatoid arthritis-associated PUK cases refractory to the above conventional immunomodulatory therapy. [36, 37] For its use in treating PUK in Crohn disease, see Pham et al. [38] . Adalimumab, a human monoclonal antibody against tumor necrosis factor, has been used with success in combination with other immunosuppressives to treat RA-associated PUK. [39]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!